Trial
NCT04159896
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Castration Levels of Testosterone
Intervention
Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Why stopped
The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-16